NCT04678830View on ClinicalTrials.gov

"Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With Long COVID-19"

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 5, 2021

Study Completion Date

July 8, 2021

Conditions
Coronavirus Disease 2019
Interventions
DRUG

Placebos

Placebos

DRUG

Leronlimab (700mg)

Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Trial Locations (2)

30501

Center for Advanced Research & Education (CARE), Gainesville

33180

Arthritis & Rheumatic Disease Specialties, Aventura

Sponsors

Lead Sponsor

CytoDyn, Inc.

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

CytoDyn, Inc.

INDUSTRY

NCT04678830 - "Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With Long COVID-19" | Biotech Hunter | Biotech Hunter